Yurak ıshemık kasallıgını davolashda stentlash va optımal medıkamentoz terapıya o‘rtasıdagı klınık-laborator farqlar
Annotatsiya
Tadqiqotning maqsadi yurak ishemik kasalligi bor bemorlarda xavf omillari va klinik-laborator ko‘rsatkichlarning o‘tkazilayotgan davolash usuli – stentlash yoki optimal medikamentoz terapiyaga bog‘liqligini o‘rganish bo‘ldi. Tadqiqotga 70 nafar bemor jalb etildi: ularning 37 nafari optimal medikamentoz terapiyada, 33 nafari esa stentlash amaliyotidan o‘tgan. Xolesterin, triglitseridlar va och qoringa qondagi glyukoza miqdori kabi biokimyoviy ko‘rsatkichlar, shuningdek, yurakning haydalish fraksiyasi kabi funksional ko‘rsatkichlar tahlil qilindi. Tadqiqot natijasida guruhlar o‘rtasida biokimyoviy va funksional ko‘rsatkichlar bo‘yicha statistik jihatdan sezilarli farqlar aniqlanmadi. Har ikkala davolash usuli ham bir xil samaradorlikni ko‘rsatdi. Stentlash davolashning muhim usuli bo‘lib qolmoqda, shu bilan birga optimal medikamentoz terapiya ham o‘z samaradorligini namoyon etmoqda.
Mualliflar haqida
Adabiyotlar ro'yxati
International Council for Standardization in Haematology (Expert Panel on Blood Rheology), ICSH recommendations for measurement of erythrocyte sedimentation rate, Journal of Clinical Pathology, 1993, March, 46, 03, 198–203, 10.1136/jcp.46.3.198, Erratum in: J Clin Pathol 1993 May;46(5):488. PMID: 8463411; PMCID: PMC501169.
Y. Li, G.Y. Cao, W.Z. Jing, J. Liu, M. Liu, Global trends and regional differences in incidence and mortality of cardiovascular disease, 1990-2019: findings from 2019 global burden of disease study, European Journal of Preventive Cardiology, 2023, 30, 03, 276–286, 10.1093/eurjpc/zwac285.
F.D. Pagani, Commentary: Left ventricular size and left ventricular assist device support outcomes: Bigger is better?, Journal of Thoracic and Cardiovascular Surgery, 2019, June, 157, 06, 2313–2314, 10.1016/j.jtcvs.2019.01.076, 30798961.
W. Qiu, J. Chen, X. Huang, The analysis of the lipid levels in patients with coronary artery disease after percutaneous coronary intervention: a one-year follow-up observational study, Lipids in Health and Disease, 2020, 19, 163, 10.1186/s12944-020-01340-5.
F. Sanchis-Gomar, C. Perez-Quilis, R. Leischik, A. Lucia, Epidemiology of coronary heart disease and acute coronary syndrome, Annals of Translational Medicine, 2016, 4, 013, 256, 10.21037/atm.2016.06.33.
T. Takada, Y. Nakata, K. Matsuura, Y. Minami, M. Kishihara, S. Watanabe, S. Shirotani, T. Abe, A. Yoshida, S. Hasegawa, K. Jujo, K. Arai, A. Suzuki, N. Hagiwara, J. Yamaguchi, Left Ventricular End- Systolic Diameter May Predict Persistent Heart Failure with Reduced Ejection Fraction, International Heart Journal, 2023, November 30, 64, 06, 1095–1104, 10.1536/ihj.23-293, 37967983.
S. Thupakula, S.S.R. Nimmala, H. Ravula, S. Chekuri, R. Padiya, Emerging biomarkers for the detection of cardiovascular diseases, Egyptian Heart Journal, 2022, 74, 01, 77, 10.1186/s43044-022-00317-2.
M. Vaduganathan, G.A. Mensah, J.V. Turco, V. Fuster, G.A. Roth, The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health, Journal of the American College of Cardiology, 2022, 80, 025, 2361–2371, 10.1016/j.jacc.2022.11.005.
William E. Boden, Peter H.Stone, To stent or not to stent? Treating angina after ISCHEMIA—why a conservative approach with optimal medical therapy is the preferred initial management strategy for chronic coronary syndromes: insights from the ISCHEMIA trial, European Heart Journal, 2021, 42, 014, 1394–1400, 10.1093/eurheartj/ehab069.002.
Y.K. Wong, H.F. Tse, Circulating Biomarkers for Cardiovascular Disease Risk Prediction in Patients With Cardiovascular Disease, Frontiers in Cardiovascular Medicine, 2021, 8, 713191, 10.3389/fcvm.2021.713191.
Copyright (c) 2024 A.X. Абдусаматов, H.M. Нуриллаева (Автор)
Ushbu asar saytida mavjud litsenziyalar Creative Commons «Attribution» (««Atribut») 4.0 Butun dunyo bo'ylab.